Nicholas J A Webb1, Thomas G Wells2, Shahnaz Shahinfar3, Rachid Massaad4, Wayne M Dankner5, Chun Lam6, Emanuela Palumbo Santoro6, Christine McCrary Sisk6, Robert O Blaustein6. 1. Department of Paediatric Nephrology and National Institute for Health Research/Wellcome Trust Children's Clinical Research Facility, University of Manchester, Manchester Academic Health Science Centre, Royal Manchester Children's Hospital, Manchester, United Kingdom; nicholas.webb@cmft.nhs.uk. 2. Arkansas Children's Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas; 3. S. Shahinfar Consulting Inc., Newtown Square, Pennsylvania; Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; 4. MSD Europe Inc., Brussels, Belgium; 5. Parexel International, Durham, North Carolina; and. 6. Merck & Co., Inc., Whitehouse Station, New Jersey.
Abstract
BACKGROUND AND OBJECTIVES: Once-daily losartan reduces BP in a dose-dependent manner and is well tolerated in hypertensive children aged 6-16 years. This study assessed the dose-response relationship, safety, and tolerability of losartan in hypertensive children aged 6 months to 6 years. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a 12-week, randomized, open-label, dose-ranging study, with a 2-year extension. Patients were randomized to losartan at the following dosages: 0.1 mg/kg per day (low), 0.3 mg/kg per day (medium), or 0.7 mg/kg per day (high). Losartan was titrated to the next dose level (to a 1.4 mg/kg per day maximum dosage, not exceeding 100 mg/d, which was not one of the three original doses offered at randomization) at weeks 3, 6, and 9 for patients who did not attain their goal BP and were not taking the highest dose. Dose response was evaluated by analyzing the slope of change in sitting systolic BP (SBP; primary end point) and diastolic BP (DBP; secondary end point) after 3 weeks compared with baseline. Adverse events (AEs) were recorded throughout. RESULTS: Of the 101 patients randomized, 99 were included in the analysis (low dose, n=32; medium dose, n=34; and high dose, n=33). Mean sitting BP decreased from baseline in the low-, medium-, and high-dose groups by 7.3, 7.6, and 6.7 mmHg, respectively, for SBP and 8.2, 5.1, and 6.7 mmHg, respectively, for DBP after 3 weeks. No dose-response relationship was established by the slope analysis on SBP (P=0.75) or DBP (P=0.64). The BP-lowering effect was observed throughout the 2-year extension. The incidence of AEs was low and comparable between groups. CONCLUSIONS:Hypertensive children aged 6 months to 6 years treated with losartan 0.1-0.7 mg/kg per day had clinically significant decreases from baseline in SBP and DBP, yet no dose-response relationship was evident. Losartan, at a dosage up to 1.4 mg/kg per day, was well tolerated.
RCT Entities:
BACKGROUND AND OBJECTIVES: Once-daily losartan reduces BP in a dose-dependent manner and is well tolerated in hypertensivechildren aged 6-16 years. This study assessed the dose-response relationship, safety, and tolerability of losartan in hypertensivechildren aged 6 months to 6 years. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a 12-week, randomized, open-label, dose-ranging study, with a 2-year extension. Patients were randomized to losartan at the following dosages: 0.1 mg/kg per day (low), 0.3 mg/kg per day (medium), or 0.7 mg/kg per day (high). Losartan was titrated to the next dose level (to a 1.4 mg/kg per day maximum dosage, not exceeding 100 mg/d, which was not one of the three original doses offered at randomization) at weeks 3, 6, and 9 for patients who did not attain their goal BP and were not taking the highest dose. Dose response was evaluated by analyzing the slope of change in sitting systolic BP (SBP; primary end point) and diastolic BP (DBP; secondary end point) after 3 weeks compared with baseline. Adverse events (AEs) were recorded throughout. RESULTS: Of the 101 patients randomized, 99 were included in the analysis (low dose, n=32; medium dose, n=34; and high dose, n=33). Mean sitting BP decreased from baseline in the low-, medium-, and high-dose groups by 7.3, 7.6, and 6.7 mmHg, respectively, for SBP and 8.2, 5.1, and 6.7 mmHg, respectively, for DBP after 3 weeks. No dose-response relationship was established by the slope analysis on SBP (P=0.75) or DBP (P=0.64). The BP-lowering effect was observed throughout the 2-year extension. The incidence of AEs was low and comparable between groups. CONCLUSIONS:Hypertensivechildren aged 6 months to 6 years treated with losartan 0.1-0.7 mg/kg per day had clinically significant decreases from baseline in SBP and DBP, yet no dose-response relationship was evident. Losartan, at a dosage up to 1.4 mg/kg per day, was well tolerated.
Authors: Nicholas J A Webb; Shahnaz Shahinfar; Thomas G Wells; Rachid Massaad; Gilbert W Gleim; Emanuela P Santoro; Christine M Sisk; Chun Lam Journal: Kidney Int Date: 2012-06-27 Impact factor: 10.612
Authors: Elke Wühl; Antonella Trivelli; Stefano Picca; Mieczyslaw Litwin; Amira Peco-Antic; Aleksandra Zurowska; Sara Testa; Augustina Jankauskiene; Sevinc Emre; Alberto Caldas-Afonso; Ali Anarat; Patrick Niaudet; Sevgi Mir; Aysin Bakkaloglu; Barbara Enke; Giovanni Montini; Ann-Margret Wingen; Peter Sallay; Nikola Jeck; Ulla Berg; Salim Caliskan; Simone Wygoda; Katharina Hohbach-Hohenfellner; Jiri Dusek; Tomasz Urasinski; Klaus Arbeiter; Thomas Neuhaus; Jutta Gellermann; Dorota Drozdz; Michel Fischbach; Kristina Möller; Marianne Wigger; Licia Peruzzi; Otto Mehls; Franz Schaefer Journal: N Engl J Med Date: 2009-10-22 Impact factor: 91.245
Authors: Joseph T Flynn; Kevin E C Meyers; Jose Pacheco Neto; Rejane de Paula Meneses; Aleksandra Zurowska; Arvind Bagga; Lionel Mattheyse; Victor Shi; Jitendra Gupte; Susan Solar-Yohay; Guangyang Han Journal: Hypertension Date: 2008-06-30 Impact factor: 10.190
Authors: Juan de Dios Ruiz-Rosado; Yong-Ung Lee; Nathan Mahler; Tai Yi; Frank Robledo-Avila; Diana Martinez-Saucedo; Avione Y Lee; Toshihiro Shoji; Eric Heuer; Andrew R Yates; Jordan S Pober; Toshiharu Shinoka; Santiago Partida-Sanchez; Christopher K Breuer Journal: FASEB J Date: 2018-06-15 Impact factor: 5.191
Authors: Nicholas J A Webb; Thomas Wells; Max Tsai; Zhen Zhao; Attila Juhasz; Caroline Dudkowski Journal: Eur J Clin Pharmacol Date: 2016-01-04 Impact factor: 2.953